DERMACYN® is based on MICROCYN® technology

The patented Microcyn® Technology mimics the same oxychlorine composition as that manufactured by neutrophils in the body’s immune system. Neutrophils are the most abundant type of white blood cells in humans and form an integral part of the immune system. It is a safe-as-saline, biocompatible and shelf-stable technology which has been validated in a variety of research and investigational studies.

Dermacyn® products are manufactured using a proprietary electrolysis process known as Microcyn® technology. Made of super-oxidized solution, Dermacyn® WoundCare products promote and facilitate the body’s natural healing processes.

Dermacyn® technology is antimicrobial and anti-inflammatory

The technology is based on a proprietary electrolysis process producing electrically charged oxychlorine small molecules designed to target a wide spectrum of single-cellular organisms including Gram positive/negative bacteria, fungi, virus and spores. The oxychlorine molecules inactivates surface proteins on the micro-organisms cell walls without causing harm to human cells. Microcyn®-based family of products have FDA and CE Mark device approvals, and possess wide clinical applications ranging from the treatment of acute and chronic wounds to various skin problem